Xhance
Payments companies reported to CMS as associated with Xhance. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xhance, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xhance
These are the largest totals companies reported as associated with Xhance. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jeffrey Bedrosian | Portland, ME | Otolaryngology | $199,815.14 |
| Naveen Bhandarkar | Orange, CA | Otolaryngic Allergy | $195,184.77 |
| James Palmer | Philadelphia, PA | Otolaryngology | $126,255.89 |
| Subinoy Das | Columbus, OH | Otolaryngology | $94,199.50 |
| Joseph Han | Norfolk, VA | Otolaryngology | $87,895.61 |
| Mark Mehle | Cleveland, OH | Otolaryngology | $86,236.20 |
| Kevin Mclaughlin | Covington, LA | Otolaryngology | $69,014.43 |
| Eric Karlin | Williamsburg, VA | Allergy & Immunology | $49,618.87 |
| Sally Bailey | Baltimore, MD | Allergy & Immunology (Internal Medicine) | $46,012.12 |
| Roheen Raithatha | New York, NY | Otolaryngology | $39,852.26 |
Prescribed Xhance?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.